[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612988":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":10,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":43,"maxAge":10,"enrollmentInfo":44,"targetDuration":47,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":59,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":10},{"fullName":5,"class":6},"Imperial College London","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants referred along upper gastrointestinal suspected cancer pathways",null,"Participants referred by GPs to secondary care for the reference test (i.e. upper gastrointestinal endoscopy, CT\u002FMRI\u002Fultrasound ± histological\u002Fcytology). Participants will be followed up (within 3 months) to determine whether they had a diagnosis of upper gastrointestinal adenocaricinoma or a normal\u002Fbenign diagnosis.",[13],"Diagnostic Test: Breath Test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Breath Test","Diagnostic Test: Breath test Participants must be fasted for a minimum of six hours prior to breath sample collection. Breath samples will be collected prior to the reference test for each participant.\n\nParticipants will then be asked to consume an Oral Stimulant Drink (OSD). The oral stimulant drink (120ml) will be composed of 25g glucose, 25g glycerol, 0.6g iron sulphate, 1.2g of \"Thicken Up\" thickener and combined amino acids (0.08g tyrosine, 1.8g phenylalanine, 2.1g glutamic acid).\n\nDiagnostic Test: Augmented breath test:\n\nParticipants will then be asked to repeat a breath sample 15 minutes after consumption of the OSD.",[9],[21],{"name":22,"affiliation":5,"role":23},"George Hanna","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Ayushi Pabari, BSc, MSc","CONTACT","02075948847","aroma@imperial.ac.uk",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":10},"Nader Bedwani, MB BCHir, MRCS",{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612988","augmented-response-of-volatile-biomarkers-in-the-assessment-of-oesophagogastric-cancer-aroma2-100612988",false,"NCT07260734","AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","AROMA2","Inclusion Criteria:\n\n* Aged ≥ 18 years old.\n* Participants referred from primary care according to the urgent suspected cancer referral guidelines for potential underlying oesophagogastric cancer a for the reference test (described below).\n* Willing and able to provide informed written consent to take part in study.\n\nExclusion Criteria:\n\n* Previous oesophageal or gastric resection\n* History of cancer within three years (other than non-melanoma skin cancers)\n* Co-morbidities preventing breath collection\n* Pregnant participants\n* Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid\n* Unable or unwilling to provide informed written consent.",true,"ALL","18 Years",{"count":45,"type":46},6000,"ESTIMATED","3 Months","OBSERVATIONAL","Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut.\n\nThe proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.",[51,52,53,54,55,56,57,58],"OESOPHAGO-GASTRIC CARCINOMA","Oesophageal Adenocarcinoma","Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","Oesophageal Cancer Nos","Oesophageal Cancer","Oesophageal Junction Cancer","Breath Tests","Volatile Organic Compound",[60,61,62,63,64,65,66,67],"Oesophageal adenocarcinoma","Gastric adenocarcinoma","Breath testing","Microbiome","Augmentation","Volatile Organic Compounds","Volatilomics","Breathomics","NOT_YET_RECRUITING","2025-11-21",{"date":71,"type":72},"2025-12-03","ACTUAL",{"date":74,"type":46},"2025-12-01",{"date":76,"type":46},"2028-11-01",{"name":5,"class":6}]